IB
IBRX
ImmunityBio, Inc.
$7.25
+1.12%
$7.5B
No data for this timeframe.
Vol
Market Cap$7.5B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders8 funds
Inst. Value$97.5M
Inst. Activity4 buys / 0 sells
Insider Activity0B / 4S
Insider Net $-$2.8M
Reddit Sentiment48° Neutral
SEC Reports4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001326110·Prev Close $7.17
Recent Activity
Jun 4, 2026
Insider
Simon Barry J. sold 23,033 shares
Director @ $7.18 ($165.3K)
May 29, 2026
short_volume
Short Volume: IBRX — 61.6% short (4.5M / 7.2M)
Short: 4,453,254 | Exempt: 30,836 | TRF Vol: 7,234,759 | Short Ratio: 61.6% | Off-exchange volume (d
May 18, 2026
SEC
ImmunityBio entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strai
8-K — Impact 5/10
Apr 9, 2026
SEC
ImmunityBio reported preliminary Q1 2026 net product revenue of $44.2 million, a 168% year-over-year increase, driven by
8-K — Impact 8/10
Apr 6, 2026
SEC
ImmunityBio submitted a comprehensive response to an FDA warning letter regarding promotional materials for its drug ANK
8-K — Impact 4/10
Mar 31, 2026
Insider
SOON-SHIONG PATRICK sold 4,606,596 shares
See remarks @ $5.43 ($25.0M)
Mar 31, 2026
Insider
SOON-SHIONG PATRICK sold 25,000,000 shares
See remarks @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — ADD
5,106,214 shares ($10.1M)
Price Targets
$13.00
+79.3% upside
Strong Buy
Current $7.25
Low $12.00
Median $12.00
High $15.00
3 analysts
$12.00
$15.00
Analyst Ratings
4Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 21, 2026 | BTIG | REITERATE | Buy → Buy |
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 5, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Apr 21, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.08 ▼ -26.3% | $-0.08 — $-0.08 | 20% YoY | 1 |
| Next Q | $-0.07 ▼ -16.7% | $-0.07 — $-0.07 | 0% YoY | 1 |
| Current FY | $-0.85 ▼ -220.8% | $-0.88 — $-0.81 | -124% YoY | 3 |
| Next FY | $0.06 ▲ +400.0% | $0.06 — $0.06 | 1 |
Latest Reports
BULLISH
8-K
5/10
ImmunityBio entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strai
May 18, 2026
BULLISH
8-K
8/10
ImmunityBio reported preliminary Q1 2026 net product revenue of $44.2 million, a 168% year-over-year increase, driven by
Apr 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $64.9M | ADD |
| MORGAN STANLEY | $10.1M | ADD |
| TWO SIGMA INVESTMENTS, LP | $9.3M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $5.0M | ADD |
| BANK OF AMERICA CORP | $4.7M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Simon Barry | SELL | $165.3K |
| Mar 31, 2026 | SOON-SHIONG PATRICK | C | $25.0M |
| Mar 31, 2026 | SOON-SHIONG PATRICK | C | $0.00 |
| Feb 24, 2026 | Simon Barry | SELL | $900.8K |
| Feb 23, 2026 | Simon Barry | SELL | $1.7M |
Reddit Sentiment
48°▼
Neutral
Bearish
Neutral
Bullish
8 institutional holders with $97.5M total value (49,246,752 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, TWO. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 32,777,257 | $64.9M | 66.6% | ADD +26.8% |
| 2 | MORGAN STANLEY | 5,106,214 | $10.1M | 10.4% | ADD +51.4% |
| 3 | TWO SIGMA INVESTMENTS, LP | 4,717,843 | $9.3M | 9.6% | ADD +80.9% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,501,666 | $5.0M | 5.1% | ADD +29.5% |
| 5 | BANK OF AMERICA CORP /DE/ | 2,382,503 | $4.7M | 4.8% | ADD +44.0% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 1,231,770 | $2.4M | 2.5% | NEW |
| 7 | WELLS FARGO & COMPANY/MN | 515,920 | $1.0M | 1.0% | ADD +90.9% |
| 8 | FMR LLC | 13,579 | $26.9K | 0.0% | NEAR_EXIT -89.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 3,373,570 | 5,106,214 | +51.4% | $10.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 2,607,860 | 4,717,843 | +80.9% | $9.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,654,776 | 2,382,503 | +44.0% | $4.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 270,245 | 515,920 | +90.9% | $1.0M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 21,817,307 | 27,655,205 | +26.8% | $68.0M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 802,563 | 2,607,860 | +224.9% | $6.4M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,775,566 | 2,299,460 | +29.5% | $5.7M | 2025-Q3 |
| UBS Group AG | ADD | 1,190,647 | 1,680,582 | +41.1% | $4.1M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 8,776,183 | 1,654,776 | -81.1% | $4.1M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 1,016,199 | — | $2.5M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 539,643 | 8,776,183 | +1526.3% | $23.2M | 2025-Q2 |
| MORGAN STANLEY | ADD | 1,895,134 | 2,972,269 | +56.8% | $7.8M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,302,083 | 1,775,566 | +36.4% | $4.7M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 23,800 | 802,563 | +3272.1% | $2.1M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 166,750 | 273,113 | +63.8% | $721.0K | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 137,913 | 14,141 | -89.7% | $37.3K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 4,005,814 | 1,895,134 | -52.7% | $5.7M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 1,041,051 | 1,348,823 | +29.6% | $4.1M | 2025-Q1 |
| MORGAN STANLEY | ADD | 2,246,892 | 4,005,814 | +78.3% | $10.3M | 2024-Q4 |
| UBS Group AG | DOUBLED | 406,433 | 1,587,689 | +290.6% | $4.1M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 106,271 | 138,605 | +30.4% | $354.8K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 568,401 | 2,246,892 | +295.3% | $8.4M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,265,981 | — | $4.7M | 2024-Q3 |
6 unique insiders with 4 transactions. Net insider value: -$2.8M ($0.00 bought, $2.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Simon Barry J. | Director | SELL | 23,033 | $7.18 | $165.3K |
| Mar 31, 2026 | SOON-SHIONG PATRICK | See remarks | C | 4,606,596 | $5.43 | $25.0M |
| Mar 31, 2026 | SOON-SHIONG PATRICK | See remarks | C | 25,000,000 | $0.00 | $0.00 |
| Feb 24, 2026 | Simon Barry J. | Director | SELL | 75,000 | $12.01 | $900.8K |
| Feb 23, 2026 | Simon Barry J. | Director | SELL | 165,000 | $10.25 | $1.7M |
| Feb 23, 2026 | Selecky Christobel | Director | M | 25,000 | $0.00 | $0.00 |
| Feb 23, 2026 | Selecky Christobel | Director | M | 25,000 | $2.98 | $74.5K |
| Feb 22, 2026 | Simon Barry J. | Director | M | 15,243 | $0.00 | $0.00 |
| Feb 22, 2026 | Simon Barry J. | Director | M | 15,243 | $0.00 | $0.00 |
| Feb 22, 2026 | Adcock Richard | CEO & President | M | 152,439 | $0.00 | $0.00 |
| Feb 22, 2026 | SOON-SHIONG PATRICK | See remarks | M | 114,329 | $0.00 | $0.00 |
| Feb 22, 2026 | LAUER REGAN J | Chief Accounting Officer | M | 4,065 | $0.00 | $0.00 |
| Feb 22, 2026 | LAUER REGAN J | Chief Accounting Officer | M | 4,065 | $0.00 | $0.00 |
| Feb 22, 2026 | SOON-SHIONG PATRICK | See remarks | M | 114,329 | $0.00 | $0.00 |
| Feb 22, 2026 | Sachs David C. | Chief Financial Officer | M | 40,650 | $0.00 | $0.00 |
| Feb 22, 2026 | Sachs David C. | Chief Financial Officer | M | 40,650 | $0.00 | $0.00 |
| Feb 22, 2026 | Adcock Richard | CEO & President | M | 152,439 | $0.00 | $0.00 |
| Feb 20, 2026 | Simon Barry J. | Director | SELL | 10,000 | $9.25 | $92.5K |
| Feb 10, 2026 | SOON-SHIONG PATRICK | See remarks | M | 274,122 | $0.00 | $0.00 |
| Feb 10, 2026 | SOON-SHIONG PATRICK | See remarks | F | 118,560 | $6.93 | $821.6K |
| Feb 10, 2026 | SOON-SHIONG PATRICK | See remarks | M | 274,122 | $0.00 | $0.00 |
| Feb 10, 2026 | Sachs David C. | Chief Financial Officer | M | 82,236 | $0.00 | $0.00 |
| Feb 10, 2026 | Sachs David C. | Chief Financial Officer | F | 42,643 | $6.93 | $295.5K |
| Feb 10, 2026 | Sachs David C. | Chief Financial Officer | M | 82,236 | $0.00 | $0.00 |
| Feb 10, 2026 | LAUER REGAN J | Chief Accounting Officer | M | 5,482 | $0.00 | $0.00 |
| Feb 10, 2026 | LAUER REGAN J | Chief Accounting Officer | F | 2,257 | $6.93 | $15.6K |
| Feb 10, 2026 | LAUER REGAN J | Chief Accounting Officer | M | 5,482 | $0.00 | $0.00 |
| Feb 10, 2026 | Adcock Richard | CEO & President | M | 274,122 | $0.00 | $0.00 |
| Feb 10, 2026 | Adcock Richard | CEO & President | F | 140,048 | $6.93 | $970.5K |
| Feb 10, 2026 | Adcock Richard | CEO & President | M | 274,122 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.8/10.
BULLISH
8-K
5/10
ImmunityBio entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for
May 18, 2026
BULLISH
8-K
8/10
ImmunityBio reported preliminary Q1 2026 net product revenue of $44.2 million, a 168% year-over-year
Apr 9, 2026
NEUTRAL
8-K
4/10
ImmunityBio submitted a comprehensive response to an FDA warning letter regarding promotional materi
Apr 6, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — increased their
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 4 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$13.00 mean target
+79.3% upside
Strong Buy (1.33)
$12.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $7.25 |
| Target Low | $12.00 |
| Target Mean | $13.00 |
| Target Median | $12.00 |
| Target High | $15.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.08 | $-0.08 | $-0.08 | 20.0% | -26.3% | 1↑ 1↓ | $0.0B | 86.2% | 1 |
| Next Q 2026-09-30 |
$-0.07 | $-0.07 | $-0.07 | 0.0% | -16.7% | 1↑ 1↓ | $0.1B | 79.8% | 1 |
| Current FY 2026-12-31 |
$-0.85 | $-0.88 | $-0.81 | -123.7% | -220.8% | 0↑ 1↓ | $0.2B | 96.3% | 3 |
| Next FY 2027-12-31 |
$0.06 | $0.06 | $0.06 | — | +400.0% | 0↑ 1↓ | $0.5B | 103.3% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.080 | |
| 7d ago | $-0.070 | -0.010 |
| 30d ago | $-0.063 | -0.017 |
| 60d ago | $-0.063 | -0.017 |
| 90d ago | $-0.070 | -0.010 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 21, 2026 | BTIG | REITERATE | Buy | Buy |
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 5, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| Feb 23, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 17, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 20, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 16, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 13, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | Jefferies | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
48°
Neutral
Bearish
Neutral
Bullish
23 mentions
5 bullish
6 bearish
20 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 22, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 21, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 17, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 17, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 18, 2026 | 3 | 57° Neutral | 1 | 0 | 3 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 12, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| Feb 28, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Feb 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Feb 24, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Feb 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 9, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 5, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Does anyone know anything about IBRX
▲ 1
💬 1
⚡ 0.5
The r/pennystocks lounge is DYING - we need to SAVE IT
▲ 1
💬 0
⚡ 0.5
How do you feel about SLS and IBRX?
▲ 1
💬 1
⚡ 0.5
IBRX VS PLTR
▲ 1
💬 0
⚡ 0.5
25 MATCH 2026 , BIGGEST LOSERS IN THE PRE- MARKET
▲ 1
💬 1
⚡ 0.5
#IBRX Thoughts ?
▲ 1
💬 0
⚡ 0.5
#IBRX thoughts 🤔
▲ 1
💬 0
⚡ 0.5
#IBRX 💯🚀💎💎
▲ 1
💬 1
⚡ 0.5
IBRX is now in play
▲ 1
💬 0
⚡ 0.5
Running IBRX
▲ 1
💬 0
⚡ 0.5
Best performing stocks year-to-date by market cap
▲ 1
💬 0
⚡ 0.5
On February 24, 2026, several Russell 2000 healthcare and biotech stocks reached new 52-week highs
▲ 0
💬 0
An interesting possible entry ($IBRX)
▲ 1
💬 0
⚡ 0.0
Uncapping a 5/10 call spread — would you here?
▲ 7
💬 5
⚡ 0.1
IBRX shorts are fucked!
▲ 2
💬 4
⚡ 0.0
May 29, 2026
short_volume
Short Volume: IBRX — 61.6% short (4.5M / 7.2M)
Short: 4,453,254 | Exempt: 30,836 | TRF Vol: 7,234,759 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: IBRX — 60.5% short (3.5M / 5.8M)
Short: 3,521,893 | Exempt: 13,606 | TRF Vol: 5,820,520 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
May 26, 2026
Clinical Trial
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
Phase Phase 3 — TERMINATED
May 22, 2026
short_volume
Short Volume: IBRX — 66.7% short (6.8M / 10.1M)
Short: 6,751,868 | Exempt: 36,105 | TRF Vol: 10,117,707 | Short Ratio: 66.7% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: IBRX — 69.0% short (8.2M / 11.8M)
Short: 8,162,930 | Exempt: 15,272 | TRF Vol: 11,829,223 | Short Ratio: 69.0% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: IBRX — 67.1% short (5.9M / 8.7M)
Short: 5,869,196 | Exempt: 47,895 | TRF Vol: 8,747,588 | Short Ratio: 67.1% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: IBRX — 68.8% short (4.2M / 6.1M)
Short: 4,173,759 | Exempt: 15,737 | TRF Vol: 6,065,114 | Short Ratio: 68.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: IBRX — 61.7% short (3.2M / 5.2M)
Short: 3,199,881 | Exempt: 19,587 | TRF Vol: 5,185,412 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_interest
FTD: IBRX — 87,758 shares ($0.7M) failed to deliver
Settlement: 20260508, Price: $7.76, FTD Value: $681,002.08, IMMUNITYBIO INC COM (DE)
May 7, 2026
earnings_calendar
IBRX Q1 2026 Earnings Scheduled — 2026-05-07
May 7, 2026
short_interest
FTD: IBRX — 84,258 shares ($0.7M) failed to deliver
Settlement: 20260507, Price: $8.38, FTD Value: $706,082.04, IMMUNITYBIO INC COM (DE)
May 6, 2026
short_interest
FTD: IBRX — 175,248 shares ($1.3M) failed to deliver
Settlement: 20260506, Price: $7.58, FTD Value: $1,328,379.84, IMMUNITYBIO INC COM (DE)
May 5, 2026
short_volume
Short Volume: IBRX — 59.2% short (3.1M / 5.3M)
Short: 3,131,662 | Exempt: 27,162 | TRF Vol: 5,286,563 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_interest
FTD: IBRX — 186,036 shares ($1.3M) failed to deliver
Settlement: 20260504, Price: $7.11, FTD Value: $1,322,715.96, IMMUNITYBIO INC COM (DE)
May 1, 2026
short_interest
FTD: IBRX — 81,295 shares ($0.6M) failed to deliver
Settlement: 20260501, Price: $7.10, FTD Value: $577,194.5, IMMUNITYBIO INC COM (DE)
May 1, 2026
short_volume
Short Volume: IBRX — 64.4% short (2.9M / 4.5M)
Short: 2,886,557 | Exempt: 36,477 | TRF Vol: 4,485,317 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
Clinical Trial
HCW9218 for Advanced Pancreatic Cancer
Phase Phase 2 — COMPLETED